Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Baihu Erzhi Tang is a Traditional Chinese Medicine (TCM) herbal formula administered in granule form. It is currently being evaluated as an adjunctive therapy to conventional Western medicine for the treatment of stage III diabetic kidney disease (DKD) in patients with type 2 diabetes mellitus. The formula is specifically indicated for patients exhibiting a TCM pattern of 'Heat and Yin Deficiency.' The name suggests a combination of two classic TCM formulas: Baihu Tang (White Tiger Decoction), which typically contains Gypsum fibrosum, Anemarrhena asphodeloides, Glycyrrhiza uralensis, and Oryza sativa; and Erzhi Wan (Two-Ultimate Pill), which consists of Ligustrum lucidum and Eclipta prostrata. The therapy aims to improve renal function, reduce the urinary albumin/creatinine ratio (UACR), and manage systemic diabetic symptoms by clearing heat and nourishing yin.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Baihu Erzhi Tang.